Pre-made Opicinumab benchmark antibody ( Whole mAb, anti-LINGO1 therapeutic antibody, Anti-LERN1/LRRN6A/MRT64/UNQ201 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-407
Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as “Anti-Lingo-1”.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||4oqt:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Multiple sclerosis;Optic neuritis|
|Development Tech||Dyax Human Phage Display|